Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

Bibliographic Details
Main Authors: Liu, Xiaoqun, Liu, Xiangdong, Qiao, Tiankui, Chen, Wei, Yuan, Sujuan
Format: Online
Language:English
Published: Dove Medical Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938144/
id pubmed-4938144
recordtype oai_dc
spelling pubmed-49381442016-07-21 Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials Liu, Xiaoqun Liu, Xiangdong Qiao, Tiankui Chen, Wei Yuan, Sujuan Original Research Dove Medical Press 2016-06-30 /pmc/articles/PMC4938144/ /pubmed/27445484 http://dx.doi.org/10.2147/OTT.S103954 Text en © 2016 Liu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Liu, Xiaoqun
Liu, Xiangdong
Qiao, Tiankui
Chen, Wei
Yuan, Sujuan
spellingShingle Liu, Xiaoqun
Liu, Xiangdong
Qiao, Tiankui
Chen, Wei
Yuan, Sujuan
Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
author_facet Liu, Xiaoqun
Liu, Xiangdong
Qiao, Tiankui
Chen, Wei
Yuan, Sujuan
author_sort Liu, Xiaoqun
title Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
title_short Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
title_full Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
title_fullStr Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
title_full_unstemmed Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
title_sort efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
description
publisher Dove Medical Press
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938144/
_version_ 1613606296817238016

Similar Items